White labcorp logo

Exciting news: Invitae joins Labcorp to expand the future of genetic testing. Learn more

Genetic testing informs breast cancer care

Hereditary genetic testing can be a powerful tool when managing patients with breast cancer and may inform surgical decisions. Receive STAT results in 7 days on average.*

Start a STAT orderGet in touch
trio of women

Transforming breast cancer care¹

Hereditary cancer genetic testing can potentially allow for more personalized care options and targeted therapies 1,2, which may improve outcomes in BRCA-positive patients, which can even extend to their families. Family members of patients with hereditary breast cancer who undergo genetic testing have the potential opportunity for early detection and prevention of cancer.

1 in 8 – breast cancer patients have genetic variant

As many as 1 in 8 breast cancer patients has a pathogenic gene variant that may impact clinical management recommendations.2,4,5


trio of women yellow bean

Help support cancer prevention and early detection for your patient’s family members.

If your patient has a positive result, their family members can have up to a 50% risk of having the same variant.

Invitae offers family variant testing for all blood relatives of patients who undergo hereditary cancer genetic testing at Invitae and have a positive result.

Now they know: Real stories

Genetic Testing for Breast Cancer: Patient Sarah Colletti and Family
“

Once I found out I had [a] BRCA1 [gene variant], I just decided. I have a chance to do something.”

- Sarah

Read Sarah's story

Test today for their tomorrow

*STAT TAT is 5-12 calendar days

References

1. Whitworth PW, Beitsch PD, Patel R, et al. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. JAMA Netw Open. 2022 Sep 1;5(9):e2232787.
2. Beitsch PD, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37(6):453-460.
3. American Society of Breast Surgeons. Consensus guideline on genetic testing for hereditary breast cancer Issued February 14, 2019.
4. Samadder NJ, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021 Feb 1;7(2):230-237.
5. Yang S, et al. Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25(10):2925-2931.
6. Naumann RW, et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecol Oncol. 2018;151(3)477-480. doi:10.1016/j.ygyno.2018.10.003.